Global Custom Market Research Reports Provider Company

phone

Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review

  • Published Date: 27 Mar 2018
  • Number of Pages: 44
  • Category: Pharmaceuticals
  • Country: United States of America
Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

Mar 15,2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
Nov 02,2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
Sep 12,2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 08,2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
May 04,2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData


List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Karyopharm Therapeutics Inc - Key Facts 5
Karyopharm Therapeutics Inc - Key Employees 6
Karyopharm Therapeutics Inc - Key Employee Biographies 7
Karyopharm Therapeutics Inc - Major Products and Services 8
Karyopharm Therapeutics Inc - History 9
Karyopharm Therapeutics Inc - Company Statement 10
Karyopharm Therapeutics Inc - Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 Company Analysis 13
Company Overview 13
Karyopharm Therapeutics Inc - Business Description 13
R&D Overview 13
Karyopharm Therapeutics Inc - SWOT Analysis 14
SWOT Analysis - Overview 14
Karyopharm Therapeutics Inc - Strengths 14
Karyopharm Therapeutics Inc - Weaknesses 15
Karyopharm Therapeutics Inc - Opportunities 16
Karyopharm Therapeutics Inc - Threats 17
Karyopharm Therapeutics Inc - Key Competitors 18
Section 3 Company Financial Ratios 19
Financial Ratios - Capital Market Ratios 19
Financial Ratios - Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios - Interim Ratios 23
Financial Ratios - Ratio Charts 24
Section 4 Companys Lifesciences Financial Deals and Alliances 25
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26
Karyopharm Therapeutics Inc, Recent Deals Summary 27
Section 5 Companys Recent Developments 28
Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress 28
Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress 31
Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 33
Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress 35
May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress 36
Apr 03, 2017: Karyopharm Announces Management Change 39
Section 6 Appendix 40
Methodology 40
Ratio Definitions 40
About GlobalData 44
Contact Us 44
Disclaimer 44

List Of Tables

List of Tables
Karyopharm Therapeutics Inc, Key Facts 5
Karyopharm Therapeutics Inc, Key Employees 6
Karyopharm Therapeutics Inc, Key Employee Biographies 7
Karyopharm Therapeutics Inc, Major Products and Services 8
Karyopharm Therapeutics Inc, History 9
Karyopharm Therapeutics Inc, Subsidiaries 12
Karyopharm Therapeutics Inc, Key Competitors 18
Karyopharm Therapeutics Inc, Ratios based on current share price 19
Karyopharm Therapeutics Inc, Annual Ratios 20
Karyopharm Therapeutics Inc, Annual Ratios (Cont...1) 21
Karyopharm Therapeutics Inc, Interim Ratios 23
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26
Karyopharm Therapeutics Inc, Recent Deals Summary 27
Currency Codes 40
Capital Market Ratios 40
Equity Ratios 41
Profitability Ratios 41
Cost Ratios 42
Liquidity Ratios 42
Leverage Ratios 43
Efficiency Ratios 43

List Of Figures

List of Figures
Karyopharm Therapeutics Inc, Performance Chart (2013 - 2017) 22
Karyopharm Therapeutics Inc, Ratio Charts 24
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 26

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective

View Report

Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports